Influenza vaccine (split virion, inactivated, Fluviral) has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Influenza vaccine (split virion, inactivated, Fluviral) studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
110502 (Flu Q Tiv-001) III A phase III, open-label, single-dose study to evaluate the safety and immunogenicity of Fluviral® trivalent split virion influenza vaccine (2007-2008 season) in adults ranging in age from 18 to 60 years and 61 years and over. Fluviral®: ID Biomedical’s* licensed trivalent split-virion influenza vaccine (Flu). *ID Biomedical has been taken over by GlaxoSmithKline Biologicals.
IDB-200-001 (FluLaval) III A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of a Thimerosal Reduced Influenza Vaccine (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in Subjects Between 18-60 and Over 60 Years of Age. Fluarix® (FluA): GlaxoSmithKline (GSK) Biologicals’ inactivated influenza vaccine. FluLaval™ TR (FluL): ID Biomedical’s* trivalent split-virion influenza vaccine. *ID Biomedical has been taken over by GSK Biologicals.
IDB-707-105 (Flu-Laval-105) III Active-control study to evaluate the safety, tolerance and immunogenicity of Fluviral™ S/F influenza vaccine in healthy adults aged 18-64 years of age. Fluviral™ S/F: ID Biomedical’s* licensed trivalent split-virion influenza vaccine (FluSF). *ID Biomedical has been taken over by GlaxoSmithKline.
IDB-707-106 (FluLaval-106) III A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Fluviral™ Influenza Vaccine in Healthy Adults 18 to 49 Years of Age. Fluviral™ (FluSF): ID Biomedical’s* trivalent, split-virion inactivated influenza vaccine *ID Biomedical has been taken over by GlaxoSmithKline Biologicals.
IDB-707-107 (FluLaval-107) III An open-label, single dose clinical study to evaluate the safety, tolerance and immunogenicity of Fluviral® trivalent split virion influenza vaccine (season 2005-2006) in adults aged between 18 and 60 and over 60. Fluviral® (FluSF): ID Biomedical’s* trivalent split-virion influenza vaccine. *ID Biomedical has been taken over by GlaxoSmithKline Biologicals.
IDB-707-108 (FluLaval-108) III A Non-Inferiority Comparison of Fluviral ™ Influenza Virus Vaccine to a US Licensed Inactivated Split-Virion Vaccine (Fluzone®) in Adults >/ 50 Years Old Living in the Community. Fluviral™: ID Biomedical’s* licensed trivalent split-virion influenza vaccine (FluSF). Fluzone®: Sanofi Pasteur’s (formerly Aventis Pasteur) licensed influenza virus vaccine (FluSA) *ID Biomedical has been taken over by GlaxoSmithKline Biologicals.
IDB-707-109 (Flu-Laval-109) III A Randomized, Double-blind Trial Comparing the Safety and Immunogenicity of Two Lots of Fluviral® Influenza Vaccine in Healthy Adults 18 to 49 Years of Age. Fluviral® (FluSF): ID Biomedical’s* trivalent inactivated split-virion influenza virus vaccine. *ID Biomedical has been taken over by GlaxoSmithKline Biologicals.
IDB-707-110 (FluLaval-110) III An Open-Label, Single Dose Clinical Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral® Trivalent Split Virion Influenza Vaccine (2006 – 2007 Season) in Adults Aged Between 18 and 60 and Over 60. Fluviral® (FluSF): ID Biomedical’s* trivalent split-virion influenza vaccine. *ID Biomedical has been taken over by GlaxoSmithKline Biologicals.
SPD707-104 (Flu-Laval-104) II A Phase II randomized study to evaluate the immunogenicity, safety and tolerance of three formulations of Fluviral®S/F influenza vaccine and Vaxigrip® in healthy adults 50-64 years of age and >/ 65 years of age. Fluviral®S/F: ID Biomedical’s* trivalent split-virion influenza vaccine (FluSF). Vaxigrip®: Sanofi-Pasteur’s trivalent split-virion inactivated influenza vaccine (Vax). *ID Biomedical has been taken over by GlaxoSmithKline Biologicals.